Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Familial hypercholesterolemia].

G Turpin1, E Bruckert

  • 1Service d'Endocrinologie-Métabolisme, Groupe Hospitalier Pitié-Salpêtrière, Paris.

Annales De Medecine Interne
|February 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hypercholesterolemia, from screening to treatment: Who, why and how to manage].

La Revue de medecine interne·2020
Same author

Psychological predictors of the combined adoption of physical exercise and dietary change among adults with hypercholesterolemia.

Revue d'epidemiologie et de sante publique·2018
Same author

Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018
Same author

[Statin treatment must be personalized].

La Revue de medecine interne·2018
Same author

[Familial hypercholesterolemia: A largely underestimated cardiovascular risk].

Annales de cardiologie et d'angeiologie·2017
Same author

Consensus statement on the management of dyslipidaemias in adults.

Annales d'endocrinologie·2017
Same journal

[Consensus Development Conference on Thrombosis and Pregnancy. 14 March 2003, Paris, France. Proceedings].

Annales de medecine interne·2004
Same journal

Kartagener's syndrome and renal failure.

Annales de medecine interne·2004
Same journal

Inflammatory pseudotumor of lymph nodes.

Annales de medecine interne·2004
Same journal

[Necrolytic migratory erythema revealing glucagonoma without diabetes].

Annales de medecine interne·2004
Same journal

[Bilateral primary non-Hodgkin's lymphomas of the adrenals].

Annales de medecine interne·2004
Same journal

[Acute "pseudo-angiocholitis" due to colonic adenocarcinoma in a man with primary sclerosis cholangitis and ulcerative colitis].

Annales de medecine interne·2004
See all related articles

Familial hypercholesterolemia causes high LDL-cholesterol due to genetic mutations, increasing atherosclerosis risk. Treatment involves diet, statins, fibrates, or LDL-apheresis to reduce cardiovascular disease.

Area of Science:

  • Cardiology
  • Genetics
  • Metabolic Disorders

Background:

  • Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma low-density lipoprotein (LDL) cholesterol.
  • LDL particles are central to atherosclerosis development and cardiovascular complications.
  • FH results from mutations affecting LDL uptake, primarily LDL receptors or apolipoprotein B100.

Purpose of the Study:

  • To outline the pathophysiology of familial hypercholesterolemia.
  • To highlight the causative genetic factors and mechanisms.
  • To discuss therapeutic strategies for managing cardiovascular risk in FH patients.

Main Methods:

  • Review of experimental, clinical, and epidemiological data.
  • Analysis of results from large-scale clinical trials with lipid-lowering drugs.

Related Experiment Videos

  • Examination of genetic mutations (LDL receptor, apolipoprotein B100) and their impact.

    • Main Results:

    • Accumulated evidence confirms LDL particles as a major cause of atherosclerosis.
    • Genetic mutations in LDL receptors or apolipoprotein B100 are key mechanisms in FH.
    • Effective lipid-lowering therapies significantly reduce cardiovascular risk.

    Conclusions:

    • FH necessitates specific interventions to mitigate cardiovascular disease risk, particularly coronary heart disease.
    • Therapeutic approaches include dietary modifications and pharmacotherapy (statins, fibrates).
    • LDL-apheresis is a crucial option for severe cases, including homozygous FH.